Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Published Date: 19 Apr 2023

Pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair responded favorably to a combination of the investigational ATR inhibitor ceralasertib and the PARP inhibitor olaparib (Lynparza).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.

2.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

3.

Mortality up for children with leukemia from lowest SES neighborhoods

4.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

5.

Vaccine shows promise for pancreatic cancer, study finds


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot